Skip to main content
. 2020 Sep 22;123(11):1616–1624. doi: 10.1038/s41416-020-01054-6

Fig. 3. Progression-free survival in the intention-to-treat population.

Fig. 3

a Kaplan–Meier estimates by treatment group. b Estimated hazard ratios (HRs) and 95% CIs from the stratified univariable Cox models in four groups. c Kaplan–Meier estimates by radiation type (ENI vs CFI). d Kaplan–Meier estimates by erlotinib administration (with erlotinib vs without erlotinib).